Drug intelligence / Profile preview

Mucoshield K19

Development stage: Preclinical
Lead developer: Swalife Biotech
Modality: Small Molecules
Administration: Oral, Topical

Overview

Mucoshield K19 is a preclinical-stage precision onco-formulation developed by Swalife Biotech. It is designed for oral health and mucosal chemoprevention, specifically targeting Keratin 19 (KRT19). KRT19 is a type I cytokeratin that is often overexpressed in various epithelial tumors and is used as a biomarker for monitoring cancer progression and response to therapy. By targeting KRT19, Mucoshield K19 aims to prevent the development or progression of mucosal lesions, particularly in the context of oral oncology.

Brand names: Mucoshield K19

Beyond the preview

Go deeper on Mucoshield K19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucoshield K19.

Explore the full profile